Centre National De La Recherche Scientifique

Assistance Publique-hopitaux De Paris

Sorbonne Université

Université De Nantes

Université D'angers

Institut National De La Sante Et De La Recherche Medicale (inserm)

Frédéric Altare

Harry Sokol

Francine Jotereau

Emmanuelle Godefroy

Guillaume Sarrabayrouse

The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4CD8ααphenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of-specific cells among CD4CD8ααT lymphocytes, from a blood sample and without needing to assess theirspecificity. T lymphocytes with a CD4CD8ααCCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease ofis particularly an inflammatory bowel disease (IBD), such as Crohn's disease.

Diagnosis, prognosis and treatment of a disease related to a decrease of

Growing community of inventors

Nantes, France

Frédéric Altare